ASLAN Pharmaceuticals Limited
ASLN · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -5.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -15.7% |
| EPS Diluted | -2.12 | -3.12 | -2.24 | -0.44 |
| % Growth | 32.1% | -39.3% | -409.1% | – |
| Operating Cash Flow | – | – | $0 | $0 |
| Capital Expenditures | – | – | $0 | $0 |
| Free Cash Flow | – | – | $0 | $0 |